Adaptimmune Therapeutics PLC: restructuring charge — Adaptimmune sells TECELRA, lete-cel, afami-cel, uza-cel to US WorldMeds for $55M cash plus up to $30M milestones

Adaptimmune Therapeutics PLC

Purchase price $55M cash at close; up to $30M in future regulatory/commercial milestone payments.
US WorldMeds to offer employment to ~50% of workforce; Adaptimmune to reduce remaining staff by ~62%.
Pre-tax restructuring costs of ~$7-8M in Q3 2025; CMO, CCO, CSO departing in August.
Adaptimmune retains preclinical PRAME, CD70, allogeneic assets; restructures to support transition.
Closing expected before August 4, 2025; financed by Oaktree and Athyrium debt.

item 1.01 item 2.05 item 5.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Adaptimmune Therapeutics PLC announced a restructuring with charges of approximately $7-8 million (approximately 62%).

Type: restructuring
Charge: approximately $7-8 million
Headcount: approximately 62%

Exact text from the filing

On July 28, 2025, Adaptimmune announced a restructuring to support the continued development by US WorldMeds of TECELRA, lete-cel, afami-cel and uza-cel and to maximize value from the Company’s remaining assets, including its PRAME and CD-70 directed T-cell therapies (the “Restructuring”). Following the Transaction, the Company plans to further reduce its remaining workforce by approximately 62%. The planned reduction in workforce is subject to consultation with employee representatives in the United Kingdom regarding the plan. The Company anticipates that the majority of the reduction in workforce will be completed during the third quarter of 2025. As a result of these actions, the Company expects to incur pre-tax costs, relating to employee severance and other employee related costs, of approximately $7-8 million.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001104659-25-071009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.